Global Safety and Efficacy Registration Study of Crinecerfont in Pediatric Patients With Classic Congenital Adrenal Hyperplasia (CAHtalyst Pediatric Study)

  • End date
    Apr 18, 2024
  • participants needed
  • sponsor
    Neurocrine Biosciences
Updated on 7 October 2022
classic congenital adrenal hyperplasia


This is a Phase 3 study to evaluate the efficacy, safety, and tolerability of crinecerfont versus placebo administered for 28 weeks in approximately 81 pediatric patients with classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency. The study consists of a 28-week double blind, placebo-controlled period, followed by 24 weeks of treatment with crinecerfont. Duration of participation is approximately 14 months.

Condition Congenital Adrenal Hyperplasia
Treatment Placebo, Crinecerfont
Clinical Study IdentifierNCT04806451
SponsorNeurocrine Biosciences
Last Modified on7 October 2022


Yes No Not Sure

Inclusion Criteria

Be willing and able to adhere to the study procedures, including all requirements at the study center, and return for the follow-up visit
Have a medically confirmed diagnosis of 21-hydroxylase deficiency CAH
Be on a stable regimen of steroidal treatment for CAH
Have elevated androgen levels
Patients of childbearing potential must be abstinent or agree to use appropriate birth control during the study

Exclusion Criteria

Have a diagnosis of any of the other forms of classic CAH
Have a history of bilateral adrenalectomy, hypopituitarism, or other condition requiring chronic glucocorticoid therapy
Have a clinically significant unstable medical condition or chronic disease other than CAH
Have a history of cancer unless considered to be cured
Have a known history of clinically significant arrhythmia or abnormalities on ECG
Have a known hypersensitivity to any corticotropin-releasing hormone antagonist
Have received an investigational drug within 30 days before initial screening or plan to use an investigational drug (other than the study drug) during the study
Have current substance dependence or substance (drug) or alcohol abuse
Have had a significant blood loss or donated blood or blood products within 8 weeks prior to the study
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note